The American College of Radiology (ACR) applauds the Centers for Medicare & Medicaid Services (CMS) for proposing steps toward a more evidence-base imaging policy in the Medicare Physician Fee Schedule proposed rule. The ACR is particularly encouraged that CMS is considering proposed actions with ACR input regarding appropriate use criteria (AUC) and clinical decision support (CDS) development and digital practice expense inputs regarding the transition from film to digital radiology.

Mirada Medical and collaborators from the University Medical Center, Groningen, The Netherlands, will present new research on quality assurance of deformable image registration (DIR) at the annual meeting of the American Association of Medical Physicists (AAPM). Accurate definition of targets and critical structures is essential for the planning and delivery of radiation therapy and radiosurgery. DIR is increasingly utilized during treatment planning to aid in this process.

PHS Technologies Group LLC, a division of PACSHealth LLC, announced that it will integrate VirtualDose CT (computed tomography) software from Virtual Phantoms Inc. into their DoseMonitor product.

Accuray Inc. and RaySearch Laboratories AB announced they have signed a long-term collaboration agreement allowing Accuray to co-market and offer the RayCare oncology information system (OIS) which is currently in development at RaySearch. Under the contract, Accuray will have the opportunity to offer RayCare in several designated major radiation therapy markets, making available a fully-integrated solution with the TomoTherapy and CyberKnife System product portfolios.


The U.S. House of Representatives July 10 passed its version of the 21st Century Cures Act (H.R. 6), designed to improve the U.S. healthcare innovation infrastructure. It was approved in a bipartisan vote of 344-77. The bill calls for providing resources to researchers working on next-generation medical devices and therapies. The legislation is aimed at addressing concerns that U.S. healthcare innovation is lagging behind the rest of the world due to large amounts of time-consuming and expensive regulatory oversight requirements that some feel are stifling innovation and the ability of startup companies to bring new products to market.


Subscribe Now